دورية أكاديمية
143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study
| العنوان: | 143P Quality of life (QoL) with palbociclib (PAL) plus endocrine therapy (ET) versus (vs) capecitabine (CAP) in luminal metastatic breast cancer (MBC) patients (pts) in the PEARL study |
|---|---|
| المؤلفون: | Kahan, Z., Gil-Gil, M., Ruiz-Borrego, M., Carrasco, E.M., Ciruelos, E.M., Muñoz, M., Bermejo De Las Heras, B., Margeli Vila, M., Anton, A., Casas, M., Calvo, L., de la Haba, J., Ramos, M., Álvarez-López, I., Gal-Yam, E., Gautier, E., Corsaro, M., Rodrigálvarez, G., Zielinski, C., Martin Jimenez, M. |
| المصدر: | In Annals of Oncology May 2020 31 Supplement 2:S66-S67 |
| قاعدة البيانات: | ScienceDirect |
كن أول من يترك تعليقا!